Clinical potential and challenges of using genetically modified cells for articular cartilage repair

Articular cartilage defects do not regenerate. Transplantation of autologous articular chondrocytes, which is clinically being performed since several decades, laid the foundation for the transplantation of genetically modified cells, which may serve the dual role of providing a cell population capable of chondrogenesis and an additional stimulus for targeted articular cartilage repair. Experimental data generated so far have shown that genetically modified articular chondrocytes and mesenchymal stem cells (MSC) allow for sustained transgene expression when transplanted into articular cartilage defects in vivo. Overexpression of therapeutic factors enhances the structural features of the cartilaginous repair tissue. Combined overexpression of genes with complementary mechanisms of action is also feasible, holding promises for further enhancement of articular cartilage repair. Significant benefits have been also observed in preclinical animal models that are, in principle, more appropriate to the clinical situation. Finally, there is convincing proof of concept based on a phase I clinical gene therapy study in which transduced fibroblasts were injected into the metacarpophalangeal joints of patients without adverse events. To realize the full clinical potential of this approach, issues that need to be addressed include its safety, the choice of the ideal gene vector system allowing for a long-term transgene expression, the identification of the optimal therapeutic gene(s), the transplantation without or with supportive biomaterials, and the establishment of the optimal dose of modified cells. As safe techniques for generating genetically engineered articular chondrocytes and MSCs are available, they may eventually represent new avenues for improved cell-based therapies for articular cartilage repair. This, in turn, may provide an important step toward the unanswered question of articular cartilage regeneration.

Received: April 5, 2011
Accepted: May 13, 2011

Correspondence to:
Henning Madry
Experimental Orthopaedics and Osteoarthritis Research
Saarland University Medical Center
Kirmbergerstr. 1, Building 37
D-66421 Homburg/Saar, Germany
henning.madry@uks.eu

Henning Madry1,2, Magali Cucchiarini1
1Experimental Orthopaedics and Osteoarthritis Research, Saarland University Medical Center and Saarland University, Homburg/Saar, Germany
2Department of Orthopaedic Surgery, Saarland University Medical Center and Saarland University, Homburg/Saar, Germany
In the early 1990s, Christopher H. Evans proposed and implemented the idea of using genetically modified cells for the treatment of arthritis (1). When synovial cells modified ex vivo via retroviral vector gene transfer were injected into the metacarpophalangeal joints of patients with rheumatoid arthritis, an interleukin-1 receptor antagonist (IL-1Ra), the active transgene product, was successfully expressed biologically active (2). This study confirmed the feasibility and laid the basis for the clinical application of genetically modified cells to human joints (3). Since then, considerable progress has been made toward our understanding of the biological and technological requirements for a successful transplantation of genetically modified cells overexpressing secreted therapeutic proteins in vitro and in vivo.

An articular cartilage defect is an area of damaged or missing cartilage. Although often caused by acute trauma, cartilage defects may also occur as a result of osteoarthritis, osteonecrosis, osteochondritis dissecans, and other pathologies (4). While traumatic defects usually are well defined and surrounded by normal articular cartilage, defects caused by osteoarthritis are often ill-defined, large, and surrounded by osteoarthritic tissue of variable quality. When restricted to the articular cartilage, the defects are termed chondral and when they reach into the subchondral bone, they have an osteochondral nature. In contrast with the very limited repairability of chondral defects (that are only partly repopulated by cells from the synovial membrane), osteochondral defects are filled with a bone marrow clot that serves as a basis for the cartilaginous repair tissue that is formed by pluripotent undifferentiated mesenchymal stem cells (MSC) arising from the bone marrow. Such articular cartilage defects may lead to the development of osteoarthritis. Since degenerative joint diseases affect more than a third of the world population and disorders of the articulations, in general, account for more than half of all chronic conditions in persons aged 60 years and over, optimized treatment strategies for articular cartilage lesions are of a high socio-economic importance (5).

Symptomatic cartilage defects require surgical treatment. Treatment options include marrow-stimulating techniques such as microfracture, Pridie drilling and abrasion arthroplasty, autologous chondrocyte transplantation, and the transfer of both autologous or allogeneic osteochondral transplants (6). Autologous chondrocyte transplantation involves the isolation and culture of articular chondrocytes that are subsequently implanted in conjunction with a supportive biodegradable matrix.

Several recent randomized controlled clinical studies confirmed the potential of autologous chondrocyte transplantation to repair large chondral defects (6). These promising data have laid a clinical basis for the experimental transplantation of genetically modified cells. In the past decades, considerable progress has been made to establish the scientific foundation for the use of such modified cells. In particular, articular chondrocytes and, more recently, MSCs have been genetically modified using nonviral or viral methods. When used in model systems of articular cartilage defects, these cells provide chondrogenic factors selectively stimulating chondrogenic processes, such as precursor cell and chondrocyte proliferation and/or the synthesis of extracellular matrix components like type-II collagen and proteoglycans. Moreover, in small and large animal models, transplantation of genetically modified cells has resulted in significant structural improvements in the repair tissue. Genetic modification of cells may therefore improve their therapeutic potential by selectively delivering biologically active compounds to a site of an articular cartilage defect. Moreover, genetically modified cells may serve the dual role of providing a repair stimulus to the host tissue and a target cell population that is capable of chondrogenesis (7).

The aim of this review is to outline options for genetic manipulation of target cells for articular cartilage repair, primarily articular chondrocytes and MSCs, and the current progress in adapting strategies based on chondrocyte transplantation for the delivery of genetically-modified cells for clinical use to treat focal articular cartilage defects and osteoarthritis.

**GENE TRANSFER IN PRECURSOR CELLS AND ARTICULAR CHONDROCYTES**

In the past two decades, articular chondrocytes and MSCs have been successfully transplanted into articular cartilage defects in patients, with the aim of improving articular cartilage repair. MSCs display some advantages compared with differentiated cells that make them attractive targets for manipulation in the goal of cartilage and bone regeneration. They can be easily isolated in a noninvasive and abundant manner from various tissues like the bone marrow, bone, adipose tissue, muscle, synovium, periosteum, and perichondrium (7). They have a potential for self-renewal and to give rise to different tissues under adapted stimuli (cartilage, bone, adipose tissue). Also, their multilin-
eage potential can be maintained in culture over time; in contrast to chondrocytes that lose their phenotype in such conditions. Remarkably, MSCs have immunosuppressive properties that might permit allo- and xenotransplantation. Preliminary clinical studies have shown the benefits of transplanting progenitor cells in human cartilage defects for instance, allowing for the formation of a stable repair tissue of fibrocartilaginous quality. As these cells, in particular articular chondrocytes, are relatively permissive to a variety of gene transfer systems, including nonviral and viral methods, researchers and clinicians have begun to evaluate the effect of gene transfer using a range of potentially therapeutic gene products. Other potential target cells for genetic modification and subsequent transplantation include cells from the tissues surrounding the joint such as cells of the synovial lining, bone, muscle, tendons, ligaments, and menisci.

Gene transfer using various reporter gene sequences has been successfully achieved in all these cell types by application of either nonviral compounds (8-20) or of viral vectors based on adenoviruses (8,11,21-38), retroviruses (8,11,21,25,39-44), and recombinant adeno-associated viruses (rAAV) (11,45-66). The latter vectors are currently the most potent gene delivery vehicles available, as they can efficiently and durably transduce articular chondrocytes (45,47,48,54-57), MSCs (45,46,58,59), synovioocytes (49-53), and other relevant cells constituting surrounding tissues (11,60-66) compared with the relatively less efficient nonviral vectors, the more immunogenic adenoviral vectors that also show very short-term gene expression capability, and the retroviral vectors that require division and pre-selection of the target cells for practicability (7). Another important point to consider in a human gene therapy trial is the ability of retroviral vectors to integrate into the host genome that might possibly lead to events of insertional mutagenesis and undesirable activation of tumor genes. Again to their advantage, rAAV vectors have been shown to be mostly maintained under stable episomal forms (67).

Key principles applied for gene-based approaches include the stimulation of anabolic pathways to enhance chondrogenesis, eg, cell proliferation and synthesis of extracellular matrix and the inhibition of catabolic pathways to prevent degradation (Table 1) (7). Among the gene candidates of value for articular cartilage repair, inhibitors of both matrix-degrading enzymes (tissue inhibitor of metalloproteinases) (9,68) and of proinflammatory cytokines (IL-1Ra, the soluble receptors sIL-1R, or sTNFR) (22,35,40,51,70), as well as chondroprotective cytokines (IL-4 and -10) (19,49,71) have been applied to inhibit catabolic pathways in vitro that are potentially activated in response to cartilage damage or injury. More relevant for the induction of cartilage repair, single or combined administration of components of the cartilage matrix or of the enzymes that synthesize them (77,78), of growth factors and their receptors (IGF-I, FGF-2, BMPs, TGF-β) (12,19,20,23,28-30,32,35,36,45,72,73), and of transcription factors (SOX5, SOX6, SOX9) (15,21,34,44,56,57) was successfully employed to activate anabolic processes in vitro. Alternatively, restoration of cell vitality and activation of proliferation in vitro have been achieved by application of IGF-I and FGF-2 (9,12,20,45,57,72), telomerase (hTERT) (75), inhibitors of apoptosis (bcl-2) (74), or HSP70 (16). Interestingly, approaches that influence several of these processes have been also successfully attempted, like combining the transfer of inhibitors of catabolism pathways and of activators of anabolic events (IGF-I/IL-1Ra or IGF-I/IL-4) (19,35,36), as well as that of activators of anabolic and proliferative processes (FGF-2/SOX9 or FGF-2/IGF-I) (57).

### Table 1. Principles, mechanisms of action and gene candidates for articular cartilage repair

| Mechanism of action                      | Target gene          | References                           |
|------------------------------------------|----------------------|--------------------------------------|
| **Inhibition of catabolic pathways**     | TIMP                 | (68,69)                              |
| inhibition of matrix-degrading enzymes   | IL-1Ra, sIL-1R, sTNFR| (22,35,40,51,70)                     |
| inhibition of proinflammatory cytokines | (IL-4, IL-10)        | (19,49,71)                           |
| **Stimulation of anabolic pathways**     |                      |                                      |
| growth factors                          | IGF-I, FGF-2         | (12,19,20,23,28-30,32,35,36,45,72,73)|
| chondrogenic transcription factors      | SOX5, SOX6, SOX9     | (15,21,34,44,56,57)                  |
| **Cytoprotection/proliferation**         |                      |                                      |
| growth factors                          | IGF-I, FGF-2         | (9,12,20,45,57,72)                   |
| inhibition of apoptosis                  | bcl-2, HSP70         | (16,74)                              |
| catalytic component of human telomerase | human telomerase     | (75)                                 |
| **Combinatorial approaches**             |                      |                                      |
| inhibition of catabolic pathways plus activation of anabolic pathways | IGF-I/IL-1Ra, IGF-I/IL-4 | (19,35,36) |
| activation of anabolic plus proliferative pathways | FGF-2/SOX9, FGF-2/IGF-I | (57,76) |

*TIMP – tissue inhibitor of metalloproteinases.

www.cmj.hr
TRANSPLANTATION OF GENETICALLY MODIFIED CELLS ONTO NORMAL ARTICULAR CARTILAGE EXPLANTS IN VITRO

Transplantation of genetically engineered articular chondrocytes onto articular cartilage explants allows for the repopulation of articular cartilage and the creation of chimerical articular surfaces in vitro (12,20,70,79,80) (Figure 1). A prerequisite for such a transplantation approach is the adherence and integration of the cells to the articular surface with continuous expression of the transgene. Enzymatic treatment of the articular surface results in an intimate integration of the transplanted cells with the articular cartilage, facilitating the formation of the interface between the two tissues (20,81). Transgenes have been shown to be active for at least 2 weeks in vitro, a time frame sufficient to allow for structural changes. While researchers usually transplant cells that have been genetically modified, Doherty et al have demonstrated that transplanted articular chondrocytes are amendable as late as 35 days after transplantation to adenoviral gene transfer in vitro (79).

The new tissue that forms is characterized by the presence of type-II collagen and proteoglycans and by the absence of type-I collagen. In this model, transplantation of chondrocytes overexpressing BMP-7 resulted in a thicker new tissue layer (80). Overexpression of a human IGF-I cDNA by genetically engineered articular chondrocytes simultaneously promoted chondrogenesis and shifted the cartilage homeostasis toward an anabolic direction, as demonstrated by the increased rates of cell proliferation and of extracellular matrix synthesis in the new tissue layer (20). Remarkably, synthesis of DNA and of glycosaminoglycans was also stimulated in the underlying explant cartilage. When fibroblast growth factor 2 (FGF-2), a mitogen for chondrocytes, was applied by transfected chondrocytes, the proliferative activities were stimulated in the new tissue without effect upon matrix glycosaminoglycan synthesis (12). These data suggest that therapeutic FGF-2 gene transfer may be applicable for the treatment of cartilage defects when cellular repopulation is the therapeutic goal, while BMP-7 may have value to enhance matrix synthesis and IGF-I for circumstances demanding a balanced increase in both chondrocyte proliferation and matrix synthesis.

Gene transfer of transcription factors has received recent interest because of the impact of these molecules on chondrogenesis. Overexpression of SOX9 via retroviral transduction was shown to stimulate type-II collagen expression in pellet cultures of human osteoarthritic articular chondrocytes (44) and in human osteoarthritic articular chondrocytes embedded in alginate spheres (21,56,57).

Figure 1.

Macroscopic view (A) and histologic section (B) of a composite culture/ex vivo articular chondrocyte transplantation model of a chondral (partial-thickness) defect. (A) Bovine articular chondrocytes were transfected with the lacZ-plasmid vector pCMVßgal and transplanted into the partial-thickness chondral defect created in a normal bovine cartilage explant. The borders of the circular chondral defect can be easily identified. The transplanted chondrocytes express the transgene on day three post-transfection which can be identified by the intensive blue color. (B) Photomicrograph of the integration site of the new tissue that has formed based on the transplantation of ex vivo genetically modified chondrocytes with the neighboring articular cartilage. Note the good integration of these two tissues, the relative hypercellularity of the new repair tissue based on the genetically modified cells in comparison with the neighboring articular cartilage, which exhibits a loss of safranin O staining at its edge toward the defect as a result of the surgically induced lesion. Original magnification ×100 (B).
TRANSPLANTATION OF GENETICALLY MODIFIED CELLS TO FOCAL ARTICULAR CARTILAGE DEFECTS IN VIVO

In this section, a number of recent studies in the field of articular cartilage repair are highlighted, with an emphasis on preclinical approaches that appear to hold most promises for a possible clinical translation.

Transplantation of genetically modified cells into articular cartilage defects in vivo has been performed in three-dimensional systems, including cell aggregates such as coagulated bone marrow aspirates (82), by encapsulation of genetically engineered cells in supportive biomaterials like alginate (9,10,83) (Figure 2), agarose (84,85), fibrin or type-I collagen gels without (86-88) or with a periosteal flap (48,89), synthetic biodegradable scaffolds (90-92), and as genetically modified tissue-engineered cartilage (7).

Kang et al were the very first to transplant chondrocytes genetically modified by a retroviral vector into an articular cartilage defect in vivo (93). Others used nonviral (94-96), adenoviral (70,82,87), retroviral (93,97-100), and rAAV vectors (101) to deliver reporter genes to defects via ex vivo approaches. While articular chondrocytes are usually transplanted (87,93,94,96,100,102,103), fibroblasts (76,104), perichondrial (95), periosteal (97,101), muscle-derived cells (98), or NIH 3T3 cells (76) have been also applied. Animal models for these marker gene studies included rats (87), rabbits (9,10,48,76,82-84,86,88,90-101,103,104), goats (89), and horses (102).

A prerequisite for the transplantation of genetically modified cells for articular cartilage repair is their capability to secrete pharmacologically active amounts of the recombinant protein (7). Yet, the cell type used for transplantation, the efficiency of the gene delivery method, and the possible influence of the biomaterial used for cell encapsulation critically affect the amount of a therapeutic protein that is produced and secreted (Figure 3). For example, IGF-I production by bovine articular chondrocytes transfected with a lipid-based method was reported to be 83 ng/107 cells/24 hours (20), while 92 ng IGF-I/107 cells/24 hours were secreted by a retrovirally transduced bovine mammary epithelial cell line selected for cells carrying the transgene (105), less than the 560 ng IGF-I/107 cells/24 hours produced by keratinocytes after retroviral transduction and selection (106). Normal human dermal fibroblasts similarly retrovirally transduced secreted 39 ng IGF-I/107 cells/24 hours but 214 ng IGF-I/107 cells/24 hours when encapsulated in alginate microspheres (107). When human normal and osteoarthritic articular chondrocytes were transduced with an rAAV IGF-I vector, 27 and 19 ng IGF-I/107 cells/24 hours were secreted (our unpublished data).

Figure 2.

Principle of alginate encapsulation of transfected, genetically modified articular chondrocytes. The alginate beads are implanted in a subchondral location. Overexpression of a therapeutic transgene results in autocrine and paracrine signals targeting the cells within the alginate sphere. When the protein is secreted, paracrine effects may stimulate the repair tissue that forms in the defect, the neighboring normal articular cartilage and, via the synovial fluid, other cells of the joint such as cells of the synovial lining and periosteal cells. In parallel, the transplanted cells are also stimulated by factors from the host. The alginate sphere is thought to protect the transplanted cells from immune responses.
Transgenes expressed via such ex vivo strategies remained active for about one month in the cartilage defects, significantly longer compared with the application of recombinant proteins. One of the earliest examples was provided by Mason et al who transferred the BMP-7 growth factor gene into a focal defect using periosteal cells transduced with a retroviral vector attached to a polyglycolic acid scaffold (39). As shown in this study, articular cartilage repair was improved at 8 and 12 weeks in vivo. A variety of therapeutic genes like BMP-2, BMP-7, IGF-I, FGF-2, and TGF-β (7,9,10,76,108-113) has been studied so far, with significant improvements in articular cartilage repair (7,9,10,76,108,110-113) (Figure 4). The choice of therapeutic genes is based on the strategy selected for improving articular cartilage repair. This, in theory, implies the use of genes that either stimulate chondrogenesis or inhibit articular cartilage degeneration. While the first approach has been studied in numerous investigations and is later described, the latter approach has been mainly tested in model systems of osteoarthritis so far. More specifically, strategies for improving individual parameters of chondrogenesis can be tailored. For example, IGF-I, a factor that simultaneously stimulates type-II collagen and proteoglycan synthesis as well as cell proliferation, may be of interest for strategies aiming at a balanced enhancement of these parameters (20), while FGF-2, which is mitogenic, may be useful to increase the pool of cells in a cartilage defect responsive to chondrogenesis (12). Initially, most of the evaluations were carried out in small animal models, such as rats (108,112) and rabbits (9,10,76,110,113). Hidaka et al (102) and Goodrich et al (114) performed the implantation of chondrocytes overexpressing BMP-7 or IGF-I in horses, respectively. Allogeneic chondrocytes transduced by an adenoviral vector carrying BMP-7 implanted into defects allowed for a better appearance of the repair tissue after 4 weeks, although no differences were found between the groups after 8 months (102). Goodrich et al showed that arthroscopically-grafted chondrocytes genetically modified by an adenovirus vector encoding equine IGF-I significantly increased IGF-I mRNA and ligand production in repair tissue in an equine model for up to 9 weeks following transplantation (114). Collagen type II expression in IGF-I treated defects was significantly increased and correlated with increased collagen type II immunoreactivity. In addition, genetic modification of chondrocytes prior to transplantation improved early (4 to 9 weeks), and to a lesser degree long-term, cartilage repair over control defects in vivo (114). Others used genetically engineered MSCs overexpressing growth factors such as BMP-4-transduced cells provided with fibrin glue in full-thickness chondral defects in rabbits (115). Histologic repair was significantly improved in defects receiving cells modified to overexpress BMP-4 compared with those where they carried a marker gene. Also, MSCs overexpressing TGF-β1 seeded into polylactide scaffolds improved extracellular matrix formation, reconstitution of the subchondral bone, and inhibited inflammatory responses (116). Finally, transplantation of MSCs transduced with the CDMP1 gene also enhanced the repair of osteochondral defects (117).

More recently, Ivkovic et al (118) implanted autologous bone marrow clots containing ex vivo adenovirally-transduced cells with a TGF-β1-expressing vector into partial-thickness chondral defects in sheep. Remarkably, improved histological, biochemical, and biomechanical parameters were evident in this preclinical animal model 6 months postoperatively. Taken together, the current literature supports several conclusions illustrating the recent progress that has been made in developing approaches for the transplantation of genetically modified cells (eg, articular chondrocytes and
MSCs) as a therapeutic option for human articular cartilage defects. First, there is convincing proof of principle that articular chondrocytes and MSCs modified by different nonviral and viral approaches can be transplanted into articular cartilage defects in vivo, allowing for sustained and clinically relevant transgene expression levels. Second, overexpression of therapeutic proteins enhances the structural features of the repair tissue of the articular cartilage and subchondral bone, being superior to unmodified or mock-transduced/-transfected cells. Third, combined overexpression of genes with complementary mechanisms of action (eg, chondrogenic and proliferative factors) is feasible, holding promises for further enhancement of articular cartilage repair. Fourth, significant benefits have been observed in preclinical animal models that are, in principle, more appropriate to study the situation in patients.

TRANSPLANTATION OF GENETICALLY MODIFIED CELLS ONTO OSTEOARTHRITIC CARTILAGE EXPLANTS IN VITRO

Ex vivo modified cells may be also applied for the resurfacing of the disrupted cartilage matrix in early stages of osteoarthritis. When transplanted onto the surface of osteoarthritic human cartilage, the modified chondrocytes may fill the gaps between the fissures, cracks, and other surface discontinuities (Figure 5). Since osteoarthritis is characterized in part by the activation of inflammatory and catabolic processes, such pathways might be inhibited by applying chondrocytes, MSCs, or synoviocytes overexpressing inhibitory molecules, such as IL-1Ra alone (70,119-124) or combined with IL-10 (124).

Baragi et al were the first to show that transplantation of human osteoarthritic chondrocytes transduced with adenoviral vectors to overexpress the human IL-1Ra onto the articular surface of osteoarthritic cartilage explant cultures was capable of protecting the cartilage from IL-1-induced extracellular matrix degradation (70). Remarkably, transduced, transplanted chondrocytes secreted significant levels of biologically active IL-1Ra that were sufficient to allow for a resistance to IL-1-induced proteoglycan degradation over the 10-day culture.

We transplanted bovine articular chondrocytes transfected with a nonviral vector overexpressing the E.coli lacZ gene onto the articular surface of human osteoarthritic cartilage explant cultures (Figure 5). Transfected, transplanted chondrocytes settled into the clefts of the osteoarthritic cartilage and restored a relatively even articular cartilage surface populated by the transplanted cells over the 7-day culture.

TRANSPLANTATION OF GENETICALLY MODIFIED CELLS IN MODELS OF OSTEOARTHRITIS IN VIVO

Transplantation of genetically modified cells in experimental models of osteoarthritis in vivo has been mostly carried out by intra-articular injection of genetically
modified cells, an approach also employed in experimental models of rheumatoid arthritis (125).

Pelletier et al (123) were among the first groups to inject retrovirally-modified synoviocytes to overexpress an IL-1Ra in a model of osteoarthritis in dogs, showing the successful reduction of the progression of the experimentally induced lesion. The same IL-1Ra gene sequence, provided alone or in combination with IL-10 via synoviocytes transduced with a retroviral vector was of further benefit to treat osteoarthritic in rabbits in vivo (124). More recently, Matsumoto et al (126) reported the efficacy of injecting intra-articularly muscle-derived stem cells modified by combined gene transfer of BMP-4 with sFlt1 (a vascular endothelial growth factor antagonist) for cartilage repair in a rat model of osteoarthritis.

In summary, there is a scarcity of experimental studies of transplanting genetically modified cells in models of osteoarthritis in vivo and, most importantly, none of the approaches described here for the treatment of osteoarthritis have been evaluated in large animal models to date.

CLINICAL GENE THERAPY TRIALS USING GENETICALLY MODIFIED CELLS

Preclinical data, as those described above, have encouraged the initiation of human clinical trials originally for arthritis, mostly based on the transfer of an IL-1Ra gene sequence (1,2,127-136) and of a sTNFR fusion protein (129,130,132,135,137-140) in the joints of patients with rheumatoid arthritis. Proof of concept and safety has been already established in the phase I clinical gene therapy study by Chris Evans in the USA and Peter Wehling in Germany (2). Autologous synovial fibroblasts transduced with a retroviral vector encoding for an IL-1Ra cDNA were injected into the 2nd-5th metacarpophalangeal joints of 9 postmenopausal women with advanced rheumatoid arthritis. Elevated amounts of IL-1Ra were present in the synovial fluid of treated patients, and cells expressing high levels of IL-1Ra were found in the synovial membrane. There were no adverse events. This investigation highly encouraged further development of gene-based approaches for the treatment of cartilage disorders. Regarding osteoarthritis, a phase I protocol is currently ongoing, based on an ex vivo approach using the retroviral transfer of transforming growth factor (TGF)-beta (130).

CHALLENGES FOR THE CLINICAL APPLICATION OF TRANSPLANTING GENETICALLY MODIFIED CELLS TO PROMOTE ARTICULAR CARTILAGE REPAIR

In conclusion, transplantation of genetically modified cells is a promising tool for the treatment of articular cartilage defects such as resulting from trauma or osteoarthritis. In the past decades, considerable progress has been made to
lay the scientific foundation for the use of modified cells. In particular, articular chondrocytes and, more recently, MSCs have been genetically modified using nonviral or viral methods. When used in model systems of cell transplantation, structural improvements occurred in the new repair tissue. Moreover, in small animal models, transplantation of genetically modified cells has yielded significant structural improvements of the repair tissue. Lately, preclinical animal models have been applied to study the effects of overexpression of therapeutic genes (118). However, to realize the full potential of these approaches in the clinics, the following issues have to be addressed:

1. the proof of the safety of this approach in preclinical and clinical trials
2. the choice of the ideal gene vector system
3. the choice of the optimal therapeutic gene(s)
4. the delivery without (eg, for large osteoarthritic lesions) or with a supportive biomaterial (for focal lesions)
5. the establishment of the optimal cell dose

For traumatic cartilage defects, single or combined overexpression of therapeutic genes, including growth and transcription factors, is feasible and results in structural improvements. Significant data have been collected in animal models of chondral and osteochondral defects. For osteoarthritis, transplantation approaches using genetically engineered cells have been less developed. Ex vivo models have already convincingly shown that genetically modified chondrocytes adhere to human osteoarthritic cartilage explants, and that inhibition of matrix degradation is possible. Animal studies using genetically modified cells for the treatment of osteoarthritis have mainly relied on the intraarticular injection of these cells, making a specific targeting of osteoarthritic areas difficult. Moreover, it remains to be seen whether areas of cartilage loss may be repopulated by such approaches, considering that the nature of the osteoarthritic loss of articular cartilage is unknown and since a simple injection of cells alone does not address other factors involved in the pathogenesis of osteoarthritis such as mechanical overload induced by axial malalignment.

Several gene transfer systems are capable of successfully modifying articular chondrocytes and MSCs, the two most promising cell types for transplantation approaches. However, each of the individual vector system has intrinsic limitations with regard to their efficacy (nonviral systems) and safety (eg, adenoviral systems) for human clinical applications. Most experts predict that initial human gene therapy trials based on the transplantation of genetically modified cells for articular cartilage repair will be conducted using rAAV vectors. The development of novel (third generation) adenoviral vectors may be another option, although significantly less immunogenic responses might be elicited when using rAAV. Vectors showing a capacity for site-specific integration have been designed for the purpose of achieving long-term gene expression, such constructs have not been tested yet in articular cartilage repair settings.

Supportive biomaterials may be used to deliver the genetically modified cells to focal articular cartilage defects, similar to the current clinical practice of treating cartilage lesions with matrix-assisted autologous chondrocyte transplantation, a technique in which the articular chondrocytes are attached to different types of scaffolds, eg, based on collagen types I/III, hyaluronic acid, polyglactin/poly-p-dioxanon, and fibrin-hyaluronan (141). Such a delivery of genetically modified chondrocytes in conjunction with biomaterials may be advantageous compared to cell delivery alone, as it allows for a spatially controlled application of the modified cells to enhance chondrogenesis. An overexpression of therapeutic genes in such tissue-engineered constructs offers the important advantage of a complete filling of the defect with a construct actively supporting chondrogenesis. Although possible side-effects intrinsic to the biomaterial on transgene expression have to be ruled out in experimental studies, the current clinical consensus on the broad advantages of matrix-assisted autologous chondrocyte transplantation suggest that genetically modified cells may rather be delivered in supportive biomaterials to focal cartilage defects. For the treatment of osteoarthritis, however, no conclusions can be drawn at the moment because of the paucity of experimental preclinical and clinical in vivo data.

Possible side-effects have also to be considered. While intra-articular injection of an BMP-2 adenoviral vector resulted in the formation of osteophytes and spread of the vector DNA to the liver, lung, and spleen, no such effects were observed when an ex vivo approach was selected injecting modified cells overexpressing BMP-2 instead (31). In fact, it appears that the therapeutic protein may exert its role in close proximity to the defect, as judged by the absence of elevated protein levels in the synovial fluid and peripheral blood and by the detection of only a few days of marker gene activity in cells adjacent to the site of the surgical approach.

The selection of therapeutic genes to specifically address individual parameters of chondrogenesis will
continues to be a challenge. Progress may come from more insights into the regulation of chondrogenesis, e.g., using genomic and proteomic profiles.

Open questions remain also in terms of finding the optimal cells dose. In the clinical protocols of autologous chondrocyte transplantation, chondrocytes are usually transplanted at densities of about 1 × 10^6 cells/cm^2. When genetically modified articular chondrocytes overexpressing IGF-I were applied in a lapine model, about 75 × 10^6 cells/cm^2 were applied, a 75-fold higher dose (10). In the clinical gene therapy study by Chris Evans, 1 × 10^6 (low dose), 1.5-5 × 10^6 (intermediate dose), and 6.5-10 × 10^6 (high dose) autologous synovial fibroblasts transduced with a retroviral vector encoding for an IL-1Ra cDNA were injected into metacarpophalangeal joints (2). Because of its similarity with the protocol currently used for autologous chondrocyte transplantation, it is likely that a dose of 1 × 10^6 cells/cm^2 may be elected as a starting point of evaluation when genetically modified chondrocytes will be transplanted to focal cartilage defects in patients.

Nevertheless, nearly three decades of experimental and clinical research to advance the principles of articular chondrocyte transplantation have yielded significant technical improvements of clinical articular chondrocyte transplantation, such as chondrocyte application in highly specialized scaffolds for optimal cell attachment and distribution in vivo (141). Many of the procedures required to constitute such ex vivo gene transfer approaches are already available for the orthopaedic surgeon. For example, cell (chondrocyte) isolation and in vitro culture – essential steps of such ex vivo protocols – are already in place. Moreover, the problem of the loss of the chondrocytic phenotype – as observed after prolonged monolayer culture (142), has been sufficiently addressed. These autologous chondrocytes could easily be genetically modified ex vivo – as shown, for example, for hematopoietic stem cells (143) – and could be implanted at the site of the cartilage defect, where a high concentration of the chondrogenic agent is needed. For the transplantation of MSC it remains to be seen whether the terminal differentiation of chondrocytes when they become hypertrophic – as observed in vitro – represents indeed a problem when implanted into articular cartilage defects in vivo (144,145).

Despite these encouraging data, application of genetically modified cells to treat cartilage defects is still not on the horizon. Issues that need to be addressed include the duration of transgene expression, extended studies with both nonviral and viral transfer systems in preclinical models of focal and osteoarthritic cartilage defects, the continuing elucidation of the benefit of using ex vivo genetically modified cells vs direct gene transfer approaches, and the ongoing identification of optimal therapeutic factors. Future studies will also have to prove the safety of such approaches, since both traumatic defects and osteoarthritis are non-lethal diseases.

A key challenge in combining both experimental (in the case of genetic modification) and clinical knowledge (in the case of articular chondrocytes transplantation) and, as a result, to translate these progresses into clinical medicine is finally to establish a safe and efficient production line, including vector manufacturing, cell isolation, and genetic modification that meets all regulatory requirements.

Ultimately, the clinical potential for genetically modified articular chondrocytes and MSCs for the treatment of articular cartilage defect is likely to be realized by advances in the following areas: 1) development of a safe, highly efficient gene delivery system with sustained duration of transgene expression, 2) identification of optimal therapeutic gene(s), 3) combination of genetically modified articular chondrocytes and/or MSCs with scaffolds that better support chondrogenesis in vivo. After safe techniques for generating these genetically engineered cells are available, such cells may eventually provide new avenues for improved cell-based therapies for articular cartilage repair. This, in turn, may provide a crucial step toward the unanswered question of articular cartilage regeneration.

Funding Based upon works supported by the Deutsche Forschungsgemeinschaft (DFG MA 2363/1-1 and/1-2 to HM and DFG CLU 55/1-1 to MC and HM), the German Osteoarthritis Foundation (Deutsche Arthrose-Hilfe; to MC and HM), the AO Foundation (HM) and the German Academy for Natural Scientists Leopoldina (BMBF-LPD 9801-10, HM).

Ethical approval Not required.

Declaration of authorship HM performed the research and wrote the manuscript. MC performed the research and wrote the manuscript.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Evans CH, Robbins PD, Ghivizzani SC, Hernond JH, Kang R, Bahnson AB, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human
Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair

14 Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res. 2002;20:169-73. Medline:11918293 doi:10.1002/jor.10083

15 Tsuchiya H, Kitoh H, Sugira F, Ishiguro N. Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun. 2003;301:338-43. Medline:12565865 doi:10.1016/S0006-291X(02)03026-7

16 Grossin L, Coumial-Henriionnet C, Pinzano A, Gaborit N, Dumas D, Etienne S, et al. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. FASEB J. 2006;20:65-75. Medline:16394269 doi:10.1096/fj.04-2889com

17 Yeh LC, Lee JC. Co-transfection with the osteogenic protein (OP)-1 gene and the insulin-like growth factor (IGF)-I gene enhanced osteoblastic cell differentiation. Biochim Biophys Acta. 2006;1763:57-63. Medline:16364466 doi:10.1016/j.bbamcr.2005.11.001

18 Zhang HN, Leng P, Wang YZ, Zhang J. Treating human meniscal fibrochondrocytes with hIGF-1 gene by liposome. Clin Orthop Relat Res. 2009;467:3175-82. Medline:19424673 doi:10.1007/s11999-009-0870-2

19 Manning K, Rachakonda PS, Rai MF, Schmidt MF. Co-expression of insulin-like growth factor-1 and interleukin-4 in an in vitro inflammatory model. Cytokine. 2010;50:297-305. Medline:20188584 doi:10.1016/j.jcyt.2010.01.010

20 Madry H, Zurakowski D, Tripell SB. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Ther. 2001;8:1443-9. Medline:11593356 doi:10.1038/sj.gt.3301535

21 Li Y, Tew SR, Russell AM, Gonzalez KR, Hardingham TE, Hawkins RE. Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng. 2004;10:575-84. Medline:15165474 doi:10.1089/107632704323061933

22 Attur MG, Dave MN, Leung MY, Cipolletta C, Meseck M, Woo SL, et al. Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol. 2002;168:2011-10. Medline:11823537

23 Smith P, Shuler FD, Georgescu HL, Ghivizzani SC, Johnstone B, Niyibizi C, et al. Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum. 2000;43:1156-64. Medline:10817570 doi:10.1002/1529-0131(200005)43:5<1156::AID-ANR26>3.0.CO;2-M

24 Goto H, Shuler FD, Lamsam C, Moller HD, Niyibizi C, Fu FH, et al. Transfer of IacZ marker gene to the meniscus. J Bone Joint Surg Am. 1999;81:918-25. Medline:10428122

25 Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH. Gene transfer to the rabbit patellar tendon: potential for genetic enhancement
of tendon and ligament healing. Gene Ther. 1996;3:1089-93. Medline:8986435

26 Lou J, Kubota H, Hotokezaka S, Ludwig FJ, Manske PR. In vivo gene transfer and overexpression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. J Orthop Res. 1997;15:911-8. Medline:9497818 doi:10.1002/j.1559-1076.1997.tb02009.x

27 Mehrara BJ, Saadeh PB, Steinbrech DS, Dudziak M, Spector JA, Greenwald JA, et al. Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. J Bone Miner Res. 1999;14:1290-301. Medline:10457261 doi:10.1359/jbmr.1999.14.8.1290

28 Nixon AJ, Brower-Toland BD, Bent SJ, Saxon RA, Wilke MJ, Robbins PD, et al. Insulinlike growth factor-I gene therapy applications for cartilage repair. Clin Orthop Relat Res. 2000;(Suppl):S201-13. Medline:11039770 doi:10.1097/00003086-200010001-00026

29 Shuler FD, Georgescu HI, NiYibizi C, Studer RK, Mi Z, Johnstone B, et al. Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes. J Orthop Res. 2000;18:585-92. Medline:11024945 doi:10.1002/jor.10251

30 Brower-Toland BD, Saxon RA, Goodrich LR, Mi Z, Robbins PD, Evans CH, et al. Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. Hum Gene Ther. 2001;12:117-29. Medline:11775494 doi:10.1089/104303401750061186

31 Gelse K, Jiang QJ, Aigner T, Ritter T, Wagner K, Poschl E, et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum. 2001;44:1943-53. Medline:11508447 doi:10.1002/1529-0131(200108)44:8<1943::AID-ART32>3.0.CO;2-Z

32 Saxer RA, Bent SJ, Brower-Toland BD, Mi Z, Robbins PD, Evans CH, et al. Gene mediated insulin-like growth factor-I delivery to the synovium. J Orthop Res. 2001;19:759-67. Medline:11562119 doi:10.1016/S0736-0266(00)00777-2

33 Musgrave DS, Pruchnic R, Bosch P, Ziran BH, Whalen J, Huard J. Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J Bone Joint Surg. 2002;84:120-7. Medline:12378177 doi:10.1002/jb.260

34 Ikeda T, Kamikura S, Mabuchi A, Kou I, Seki S, Takato T, et al. The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage. Arthritis Rheum. 2004;50:3561-73. Medline:15529345 doi:10.1002/art.20611

35 Haupt JL, Frisbie DD, McIlwraith CW, Robbins PD, Ghivizzani S, Evans CH, et al. Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res. 2005;23:118-26. Medline:15607883 doi:10.1016/j.ortho.2004.06.020

36 Nixon AJ, Haupt JL, Frisbie DD, Morisset SS, McIlwraith CW, Robbins PD, et al. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy. Gene Ther. 2005;12:177-86. Medline:15578043 doi:10.1038/sj.gt.3302396

37 Steinert AF, Palmer GD, Capito R, Hofstatter JG, Pilapil C, Ghivizzani SC, et al. Genetically enhanced engineering of meniscus tissue using ex vivo delivery of transforming growth factor-beta 1 complementary deoxiribonucleic acid. Tissue Eng. 2007;13:2227-37. Medline:17561802 doi:10.1089/teng.2006.0207

38 Steinert AF, Proffen B, Kunz M, Hendrich C, Ghivizzani SC, Noth U, et al. Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Rheum. 2009;11:R148. Medline:19799789 doi:10.1186/ar2822

39 Mason JM, Brentbart AS, Barcia M, Porti D, Pergolizzi RG, Grande DA. Cartilage formation and bone regeneration using gene-enhanced tissue engineering. Clin Orthop Relat Res. 2000;(Suppl):S171-8. Medline:11039767 doi:10.1186/ar2822

40 Roessler BJ, Hartman JW, Vailance DK, Latta JM, Janich SL, Davidson BL. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther. 1995;6:307-16. Medline:7779914 doi:10.1089/hum.1995.6.3-307

41 Baltzer AW, Whalen JD, Muzzonegro T, Georgescu HI, Robbins PD, Evans CH. In vitro transduction of human osteoblast cell populations with retroviral vectors [in German]. Z Rheumatol. 1999;58:88-94. Medline:10408069 doi:10.1002/1529-0131(200108)44:8<1943:AID-ART332>3.0.CO;2-Z

42 Hildebrand KA, Deie M, Allen CR, Smith DW, Georgescu HI, Evans CH, et al. Early expression of marker genes in the rabbit median collateral and anterior cruciate ligaments: the use of different viral vectors and the effects of injury. J Orthop Res. 1999;17:37-42. Medline:10073645 doi:10.1016/j.jor.2000.01.003

43 Goto H, Shuler FD, NiYibizi C, Fu FH, Robbins PD, Evans CH. Gene therapy for meniscal injury: enhanced synthesis of proteoglycan and collagen by meniscal cells transduced with a TGFbeta1 gene. Osteoarthritis Cartilage. 2000;8:266-71. Medline:10903880 doi:10.1016/s0923-8484(00)00030-0

44 Tew SR, Li Y, Pothacharoen P, Tweats LM, Hawkins RE, Hardingham TE. Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage. 2005;13:80-9. Medline:15639641 doi:10.1016/j.joca.2004.10.011

45 Cucchiari M, Madry H, Ma C, Thurn T, Zurakowski D, Menger MD, et al. Improved tissue repair in articular cartilage defects in vivo by rAAV-mediated overexpression of human fibroblast growth factor 2. Mol Ther. 2005;12:229-38. Medline:16043094 doi:10.1016/j.molther.2005.03.012

46 Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X, Chu CR. Adeno-
associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. Gene Ther. 2007;14:804-13. Medline:17344902 doi:10.1038/sj.gt.3302938

Madry H, Cucchiarini M, Tervilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther. 2003;14:393-402. Medline:12659680 doi:10.1089/104303321208998

Yokoo N, Saito T, Usugi M, Kobayashi N, Xin KQ, Okuda K, et al. Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector. Arthritis Rheum. 2005;52:164-70. Medline:15641065 doi:10.1002/art.20739

Jennings K, Miyamae T, Traister R, Marinov A, Jacquet C, Sany J, Jorgensen C, et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther. 2005;11:600-7. Medline:15771962 doi:10.1089/jmt.2004.20.020

Goater J, Muller R, Kollas G, Firestein GS, Sany J, O’Keefe RJ, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol. 2000;27:983-9. Medline:10782827

Zhang HG, Xie J, Yang P, Wang Y, Xu L, Liu D, et al. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther. 2000;11:2431-42. Medline:11096446 doi:10.1089/104303400750038525

Hiraide A, Yokoo N, Xin KQ, Okuda K, Mizukami H, Ozawa K, et al. Repair of articular cartilage defect by intraarticular administration of basic fibroblast growth factor gene, using adeno-associated virus vector. Hum Gene Ther. 2005;16:1413-21. Medline:16390272 doi:10.1089/hum.2005.16.1413

Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C, et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther. 2002;13:1179-88. Medline:12133271 doi:10.1089/1043034020038961

Arai Y, Kubo T, Fushiki S, Mazda O, Nakai H, Iwaki Y, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol. 2000;27:979-82. Medline:10782826

Ulrich-Vinther M, Maloney MD, Goater JJ, Soballe K, Goldring MB, O’Keefe RJ, et al. Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular cartilage. Arthritis Rheum. 2002;46:2095-104. Medline:12209514 doi:10.1002/art.10433

Cucchiarini M, Thurn T, Weimer A, Kohn D, Tervilliger EF, Madry H. Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor Sox9. Arthritis Rheum. 2007;56:158-67. Medline:17195218 doi:10.1002/art.22299

Cucchiarini M, Tervilliger EF, Kohn D, Madry H. Remodelling of human osteoarthritic cartilage by FGF-2, alone or combined with Sox9 via rAAV gene transfer. J Cell Mol Med. 2009;13:2476-88. Medline:18705695 doi:10.1111/j.1440-1773.2008.00474.x

Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankensson KD, Pace JM, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science. 2004;303:1198-201. Medline:14976317 doi:10.1126/science.1088757

Ito H, Goater JJ, Tyiapatanaputi P, Rubery PT, O’Keefe RJ, Schwarz EM. Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells. Gene Ther. 2004;11:34-41. Medline:14681695 doi:10.1038/sj.gt.3302102

Basile P, Dadali T, Jacobson J, Haslund S, Ulrich-Vinther M, Soballe K, et al. Freeze-dried tendon allografts as tissue-engineering scaffolds for Gdf5 gene delivery. Mol Ther. 2008;16:466-73. Medline:18180771 doi:10.1038/sj.mt.6300395

Arsic N, Zacchigna S, Zentilin L, Ramirez-Conrea G, Pattarini L, Salvi A, et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther. 2004;10:844-54. Medline:15509502 doi:10.1089/hum.2005.16.1413

Madry H, Cucchiarini M, Kaul G, Kohn D, Tervilliger EF, Trippel SB. Meniscis are efficiently transduced by recombinant adeno-associated virus vectors in vitro and in vivo. Am J Sports Med. 2004;32:1860-5. Medline:15572313 doi:10.1177/0363546504265189

Ito H, Koefoed M, Tyiapatanaputi P, Gromov K, Goater JJ, Carmouche J, et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med. 2005;11:291-7. Medline:15711561 doi:10.1038/nm1190

Wang XT, Liu PY, Xin KQ, Tang JB. Tendon healing in vitro: bFGF gene transfer to tenocytes by adeno-associated viral vectors promotes expression of collagen genes. J Hand Surg Am. 2005;30:1255-61. Medline:16344185 doi:10.1016/j.jhsa.2005.06.001

Tang JB, Cao Y, Zhu B, Xin KQ, Wang YT, Liu PY. Adeno-associated virus-2-mediated bFGF gene transfer to digital flexor tendons significantly increases healing strength. An in vivo study. J Bone Joint Surg Am. 2008;90:1078-89. Medline:18451401 doi:10.2106/JBJS.F.01188

Cucchiarini M, Schetting S, Tervilliger EF, Kohn D, Madry H. rAAV-mediated overexpression of FGF-2 promotes cell proliferation, survival, and alpha-SMA expression in human mesenchial lesions. Gene Ther. 2009;16:1363-72. Medline:19641531 doi:10.1038/gt.2009.91

Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-108. Medline:8892935

Kafienah W, Al-Fayez F, Hollander AP, Barker MD. Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach. Arthritis Rheum. 2003;48:709-18. Medline:12632424 doi:10.1002/art.10842

Bondeson J, Launder S, Wainwright S, Amos N, Evans A, Hughes
C, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritic synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol. 2007;34:523-33. Medline:17295438

70 Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler B.I. Transplantation of transduced chondrocytes protects articular cartilage from interleukin-1-induced extracellular matrix degradation. J Clin Invest. 1995;96:2454-60. Medline:7593634 doi:10.1172/JCI118303

71 Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol. 2001;166:3499-505. Medline:11207309

72 Schmal H, Mehlhorn AT, Zwingmann J, Muller CA, Stark Gb, Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Doherty PJ, Zhang H, Tremblay L, Manolopoulos V, Marshall KW. Resurfacing of articular cartilage explants with genetically-modified human chondrocytes in vitro. Osteoarthritis Cartilage. 1998;6:153-9. Medline:9682781 doi:10.1038/joca.1998.1007

80 Hidaka C, Quitoriano M, Warren RF, Crystal RG. Enhanced matrix synthesis and in vitro formation of cartilage-like tissue by genetically modified chondrocytes expressing BMP-7. J Orthop Res. 2001;19:751-8. Medline:11562118 doi:10.1016/S0736-0266(01)00019-5

81 Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Ther. 2000;7:286-91. Medline:10694808 doi:10.1038/sj.gt.3301086

82 Pascher A, Palmer GD, Steinert A, Oligno T, Gouze E, Gouze JN, et al. Gene delivery to cartilage defects using coagulated bone marrow aspirate. Gene Ther. 2004;11:133-41. Medline:14712297 doi:10.1038/sj.gt.3302155

83 Fragonas E, Valente M, Pozzi-Mucelli M, Toffanin R, Rizzo R, Silvestri F, et al. Articular cartilage repair in rabbits by using suspensions of allogeneic chondrocytes in alginate. Biomaterials. 2000;21:795-801. Medline:10721748 doi:10.1016/S0142-9612(99)00241-0

84 Rahofth B, Weisser J, Sternkopf F, Aigner T, von der Mark K, Brauer Transplantation of allograft chondrocytes embedded in agarose gel into cartilage defects of rabbits. Osteoarthritis Cartilage. 1998;6:50-65. Medline:9616439 doi:10.1038/joca.1997.0092

85 Hunter CJ, Levenston ME. Maturation and integration of tissue-engineered cartilages within an in vitro defect repair model. Tissue Eng. 2004;10:736-46. Medline:15265290 doi:10.1063/1.174348310

86 Kawamura S, Wakitani S, Kimura T, Maeda A, Caplan AI, Shino K, et al. Cartilage repair: Rabbit experiments with a collagen gel-biomatrix and chondrocytes cultured in it. Acta Orthop Scand. 1998;69:56-62. Medline:9524520 doi:10.1089/1076327041348310

87 Ikeda T, Kubo T, Nakashima T, Arai K, Kubayashi K, Maeda O, et al. Ex vivo gene delivery using an adenovirus vector in treatment for cartilage defects. J Rheumatol. 2000;27:990-6. Medline:10782828

88 Perka C, Schultz O, Spitzer RS, Lindenhayn K. The influence of transforming growth factor beta1 on mesenchymal cell repair of full-thickness cartilage defects. J Biomed Mater Res. 2000;52:543-52. Medline:11007623 doi:10.1002/1097-4636(20001205)52:3<543::AID-JBMR13>3.0.CO;2-2

89 Driesang IM, Hunziker EB. Delamination rates of tissue flaps used in articular cartilage repair. J Orthop Res. 2000;18:909-11. Medline:11192250 doi:10.1002/jor.1100180609

90 Freed LE, Grande DA, Lingbin Z, Emmanual J, Marquis JC, Langer R. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds. J Biomed Mater Res. 1994;28:891-9. Medline:7983087 doi:10.1002/jbm.820280808

91 Perka C, Sittinger M, Schultz O, Spitzer RS, Schlenzka D, Burmester GR. Tissue engineered cartilage repair using cryopreserved and noncryopreserved chondrocytes. Clin Orthop Relat Res. 2000;(378):245-54. Medline:10987000 doi:10.1097/00003086-
Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair

103 Baragi VM, Renkiewicz RR, Qi L, Brammer D, Riley JM, Sigler RE, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthritis Cartilage. 1997;5:275-82. Medline:9404472 doi:10.1016/S1063-4584(97)80023-4

104 Lee KH, Song SU, Hwang TS, Yi Y, Oh JS, Lee JY, et al. Regeneration of cartilage by cell-mediated gene therapy using transforming growth factor beta 1-producing fibroblasts. Hum Gene Ther. 2001;12:1805-13. Medline:11560773 doi:10.1089/104303401750476294

105 Romagnolo D, Akers RM, Wong EA, Boyle PL, McFadden TB, Turner JD. Overexpression of ovine insulin-like growth factor-I stimulates autonomous autocrine or paracrine growth in bovine mammary-derived epithelial cells. Mol Endocrinol. 1992;6:1774-80. Medline:1480169 doi:10.1021/mc.61.1774

106 Eming SA, Snow RG, Yarmush ML, Morgan JR. Targeted expression of insulin-like growth factor to human keratinocytes: modification of the autocrine control of keratinocyte proliferation. J Invest Dermatol. 1996;107:113-20. Medline:8752849 doi:10.1111/1523-1747.ep12298351

107 Patel RS, Temu TM, Jeannart L, Morgan JR, Lysaght MJ. A localizable, biological-based system for the delivery of bioactive IGF-1 utilizing microencapsulated genetically modified human fibroblasts. ASAIO J. 2009;55:259-65. Medline:19390433 doi:10.1097/MAT.0b013e31819b0365

108 Park J, Gelse K, Frank S, von der Mark K, Aigner T, Schneider H. Transgene-activated mesenchymal cells for articular cartilage repair: a comparison of primary bone marrow- and periosteum- derived cells. J Gene Med. 2006;8:112-25. Medline:16142704 doi:10.1002/jgm.826

109 Turgeman G, Pittman DD, Muller R, Kurkalli G, Zhou S, Pelled G, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med. 2001;3:240-51. Medline:11437329 doi:10.1002/1521-0226(200105)3:3<240::AID-JGM181>3.0.CO;2-A

110 Che JH, Zhang ZR, Li GZ, Tan WH, Bai XD, Qu FJ. Application of tissue-engineered cartilage with BMP-7 gene to repair knee joint cartilage injury in rabbits. Knee Surg Sports Traumatol Arthosc. 2010;18:496-503. Medline:19855958 doi:10.1007/s00167-009-0962-2

111 Gelse K, Muhle C, Franke O, Park J, Jehle M, Durst K, et al. Cell-based resurfacing of large cartilage defects: long-term evaluation of grafts from autologous transgene-activated periosteal cells in a porcine model of osteoarthritis. Arthritis Rheum. 2008;58:475-88. Medline:18240212 doi:10.1002/art.23124

112 Gysin R, Wergedal JE, Sheng MH, Kasukawa Y, Miyakoshi N, Chen ST, et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Ther. 2002;9:991-9. Medline:12101429 doi:10.1038/sj.gt.3301772

www.cmj.hr
113 Vogt S, Wexel G, Schiller U, Uebelacker P, Wagner B, et al. The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials. 2009;30:2385-92. Medline:19185914 doi:10.1016/j.biomaterials.2009.01.016

114 Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J Bone Joint Surg Br. 2007;89:672-85. Medline:17540757 doi:10.1302/0301-620X.89B5.18343

115 Kuroda R, Usas A, Kubo S, Corai C, Peng H, Rose T, et al. Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. Arthritis Rheum. 2006;54:433-42. Medline:16447218 doi:10.1002/art.21632

116 Guo X, Zheng Q, Yang S, Shao Z, Yuan Q, Pan Z, et al. Repair of full-thickness articular cartilage defects by cultured meniscal stem cells transplanted with the transforming growth factor beta 1 gene. Biomed Mater. 2006;1:206-15. Medline:18458408 doi:10.1088/1748-6041/1/4/006

117 Katayama R, Wakitani S, Tsumaki N, Morita Y, Matsushita I, Gejo R, et al. Repair of articular cartilage defects in rabbits using CDMP1 gene-transfected autologous meniscal cells derived from bone marrow. Rheumatology (Oxford). 2004;43:980-5. Medline:15187242 doi:10.1093/rheumatology/keh240

118 Ivkovic A, Pascher A, Hudetz D, Maticic D, Jelic S, Dickinson S, et al. Articular cartilage repair by genetically modified bone marrow aspirate in sheep. Gene Ther. 2010;17:779-89. Medline:20220780 doi:10.1038/gt.2010.16

119 Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, et al. Intraarticular expression of biologically active interleukin 1-receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A. 1993;90:10764-8. Medline:8248169 doi:10.1073/pnas.90.22.10764

120 Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther. 1994;1:64-9. Medline:7584062

121 Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS Jr, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. 1996;93:402-6. Medline:8617986

122 Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol. 1996;156:3558-62. Medline:8617986

123 Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997;40:1012-9. Medline:9182910 doi:10.1002/art.178040604

124 Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res. 2004;22:742-50. Medline:15183429 doi:10.1016/j.jores.2003.12.007

125 Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther. 2002;6:591-600. Medline:12409257 doi:10.1016/S1525-0016(02)90711-2

126 Matsumoto T, Cooper GM, Gharabeb B, Meszaros LB, Li G, Usas A, et al. Cartilage repair in a rat model of osteoarthritis through intrarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum. 2009;60:1390-405. Medline:19404941 doi:10.1002/art.24443

127 Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop Relat Res. 2000;(Suppl):5300-7. Medline:11039783 doi:10.1007/0-387-95000-1_49

128 Evans CH, Lee JS, Oligino TJ, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther. 2004;11:379-89. Medline:14724685 doi:10.1038/sj.gt.3302196

129 Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next? Arthritis Rheum. 2006;54:1714-29. Medline:16729280 doi:10.1002/art.21886

130 Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy’s first death. Arthritis Res Ther. 2008;10:110. Medline:18510784 doi:10.1186/ar2411

131 Evans CH, Ghivizzani SC, Oligino TJ, Robbins PD. Gene therapy for autoimmune disorders. J Clin Immunol. 2000;20:334-46. Medline:11051275 doi:10.1073/pnas.90.22.10764

132 Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy: what have we accomplished and where do we go from here? J Rheumatol Suppl. 2005;72:17-20. Medline:15660458

133 Wehling P, Reinecke J, Baldwin AWJ, Granath M, Schultz KP, Schultz C, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009;20:97-101. Medline:1896219 doi:10.1089/hum.2008.075

134 Evans CH, Ghivizzani SC, Robbins PD. The 2003 Nicolas Andry Award. Orthopaedic gene therapy. Clin Orthop Relat Res. 2004;(429):316-29. Medline:15577504 doi:10.1097/01.blo.0000148854.14399.ec

135 Evans CH, Ghivizzani SC, Herndon JH, Robbins PD. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg. 2005;13:230-42. Medline:16112980

136 Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther. 2003;10:902-11. Medline:12732875 doi:10.1038/sj.gt.3302040

137 Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, et al. Local delivery of a recombinant adenoassociated...
vector containing a tumour necrosis factor alpha antagonist
gene in inflammatory arthritis: a phase 1 dose-escalation
safety and tolerability study. Ann Rheum Dis. 2009;68:1247-54.
Medline:18678578 doi:10.1136/ard.2008.089375
138 Kaiser J. Clinical research. Death prompts a review of gene therapy
vector. Science. 2007;317:580. Medline:17673625 doi:10.1126/
science.317.5838.580
139 Williams DA. RAC reviews serious adverse event associated with
AAV therapy trial. Mol Ther. 2007;15:2053-4. Medline:18026178
doi:10.1038/sj.mt.6300352
140 Williams DA. NIH recombinant DNA Advisory Committee continues
to ponder adverse event associated with AAV gene therapy trial.
Mol Ther. 2008;16:427-8. Medline:18297091 doi:10.1038/mt.2008.2
141 Brittberg M. Cell carriers as the next generation of cell
therapy for cartilage repair: a review of the matrix-
induced autologous chondrocyte implantation procedure.
Am J Sports Med. 2010;38:1259-71. Medline:19966108
doi:10.1177/0363546509346395
142 von der Mark K, Gauss V, von der Mark H, Muller P. Relationship
between cell shape and type of collagen synthesised as
chondrocytes lose their cartilage phenotype in culture. Nature.
1977;267:531-2. Medline:5599477 doi:10.1038/267531a0
143 Naldini L. Ex vivo gene transfer and correction for cell-based
therapies. Nat Rev Genet. 2011;12:301-15. Medline:21445084
doi:10.1038/nrg2985
144 Tuan RS. Stemming cartilage degeneration: adult mesenchymal
stem cells as a cell source for articular cartilage tissue engineering.
Arthritis Rheum. 2006;54:3075-8. Medline:17009225 doi:10.1002/
art.22148
145 Loken S, Jakobsen RB, Aroen A, Heir S, Shahdadfar A, Brinchmann
JE, et al. Bone marrow mesenchymal stem cells in a hyaluronan
scaffold for treatment of an osteochondral defect in a rabbit
model. Knee Surg Sports Traumatol Arthrosc. 2008;16:896-903.
Medline:18592218 doi:10.1007/s00167-008-0566-2